Zobrazeno 1 - 10
of 63
pro vyhledávání: '"MITSUKO SUZUKI"'
Autor:
Nana Ama Amissah, Sophie Gryseels, Nicholas J Tobias, Bahram Ravadgar, Mitsuko Suzuki, Koen Vandelannoote, Lies Durnez, Herwig Leirs, Timothy P Stinear, Françoise Portaels, Anthony Ablordey, Miriam Eddyani
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 8, Iss 9, p e3148 (2014)
The reservoir and mode of transmission of Mycobacterium ulcerans, the causative agent of Buruli ulcer, still remain a mystery. It has been suggested that M. ulcerans persists with difficulty as a free-living organism due to its natural fragility and
Externí odkaz:
https://doaj.org/article/8640b1c9efdc48e3934b0c9b6906af41
Autor:
Kohei Shitara, Hiroyoshi Nishikawa, Shohei Koyama, Akihiro Sato, Masashi Wakabayashi, Takashi Ikeno, Tsukiko Higuchi, Miki Fukutani, Mitsuko Suzuki, Yoichi Naito, Kenichi Harano, Hiroya Taniguchi, Yasutoshi Kuboki, Daisuke Kotani, Noboru Yamamoto, Kota Itahashi, Akihito Kawazoe
Figure S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d939d0282f925af692b78a921ac8b30
https://doi.org/10.1158/1078-0432.22483994.v1
https://doi.org/10.1158/1078-0432.22483994.v1
Autor:
Kohei Shitara, Hiroyoshi Nishikawa, Shohei Koyama, Akihiro Sato, Masashi Wakabayashi, Takashi Ikeno, Tsukiko Higuchi, Miki Fukutani, Mitsuko Suzuki, Yoichi Naito, Kenichi Harano, Hiroya Taniguchi, Yasutoshi Kuboki, Daisuke Kotani, Noboru Yamamoto, Kota Itahashi, Akihito Kawazoe
Purpose:This is a phase Ib trial of TAS-116, an oral HSP90 inhibitor, plus nivolumab for colorectal cancer and other solid tumors.Patients and Methods:Enrolled patients received TAS-116 plus nivolumab in a dose-finding part to estimate the recommende
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac054405e102c956afa360f789d24781
https://doi.org/10.1158/1078-0432.c.6531290
https://doi.org/10.1158/1078-0432.c.6531290
Autor:
Kohei Shitara, Hiroyoshi Nishikawa, Shohei Koyama, Akihiro Sato, Masashi Wakabayashi, Takashi Ikeno, Tsukiko Higuchi, Miki Fukutani, Mitsuko Suzuki, Yoichi Naito, Kenichi Harano, Hiroya Taniguchi, Yasutoshi Kuboki, Daisuke Kotani, Noboru Yamamoto, Kota Itahashi, Akihito Kawazoe
Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d4216aaa443ce1feb8a25c6fe785586
https://doi.org/10.1158/1078-0432.22484009.v1
https://doi.org/10.1158/1078-0432.22484009.v1
Autor:
Hiroya Taniguchi, Kota Itahashi, Hiroyoshi Nishikawa, Yoichi Naito, Akihito Kawazoe, Miki Fukutani, Kohei Shitara, Kenichi Harano, Takashi Ikeno, Yasutoshi Kuboki, Shohei Koyama, Masashi Wakabayashi, Tsukiko Higuchi, Noboru Yamamoto, Akihiro Sato, Daisuke Kotani, Mitsuko Suzuki
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(24)
Purpose: This is a phase Ib trial of TAS-116, an oral HSP90 inhibitor, plus nivolumab for colorectal cancer and other solid tumors. Patients and Methods: Enrolled patients received TAS-116 plus nivolumab in a dose-finding part to estimate the recomme
Autor:
Yasutoshi Kuboki, Miki Fukutani, Daisuke Kotani, Hiroyoshi Nishikawa, Kenichi Harano, Noboru Yamamoto, Hikari Shima, Mitsuko Suzuki, Masashi Wakabayashi, Kohei Shitara, Tsukiko Higuchi, Akihiro Sato, Yoichi Naito, Akihito Kawazoe, Shogo Nomura, Hiroya Taniguchi
Publikováno v:
Journal of Clinical Oncology. 38:4044-4044
4044 Background: Regulatory T cells (Tregs) potentially induce the resistance of anti-PD1/PD-L1 inhibitors (A-PD1). TAS-116, a novel HSP90 inhibitor, enhanced antitumor immunity via reducing Tregs in vitro and in vivo. Combination of TAS-116 plus A-P
Publikováno v:
創価人間学論集. 7:65-89
Autor:
Mitsuko, SUZUKI
Publikováno v:
創価人間学論集. 7:45-63
Autor:
Akihiro Sato, Takeshi Kato, Taito Esaki, Takayuki Yoshino, Nozomu Fuse, Martina I. Lefterova, Hideaki Bando, Shogo Nomura, Tomohiro Nishina, Satoshi Fujii, Yoshito Komatsu, Ken Kato, Justin I. Odegaard, Hiromichi Ebi, Eiji Shinozaki, Yoshiaki Nakamura, Tomoko Jogo, Mitsuko Suzuki
Publikováno v:
Journal of Clinical Oncology. 37:TPS3156-TPS3156
TPS3156 Background: Approximately 7% of advanced solid malignancies have FGFR gene alterations. However, standard treatment for FGFR-altered malignancies has not been established. Moreover, circulating tumor DNA (ctDNA) analysis has a potential to ac
Autor:
Osamu Morinaga, Nobuo Ohta, Kofi Dadzie Kwofie, Maxwell M. Sakyiamah, Takuhiro Uto, Yasuchika Yamaguchi, William K. Anyan, Frederic Aboagye, Michael Amoa-Bosompem, Irene Ayi, Alfred Ampomah Appiah, Kwadwo K. Frempong, Taizo Yamashita, Frederick Ayertey, Kenji Yoza, Daniel A. Boakye, Philip Atchoglo, Isaac Tuffour, Kwadwo A. Koram, Alexander K. Nyarko, Kofi Baffour-Awuah Owusu, Nguyen Huu Tung, Mitsuko Suzuki, Shoji Yamaoka, Richard Adegle, Satoru Karasawa, Regina Appiah-Opong, Dominic Edoh, Yukihiro Shoyama
Publikováno v:
Tetrahedron Letters. 56:7158-7160
The strong anti-trypanosomal active compound, molucidin, contains a spirolactone tetracyclic iridoid skeleton and is isolated from Morinda lucida as an enantiomer of oruwacin, which is isolated from the same plant. To confirm the absolute configurati